The biotechnology space is extremely competitive, particularly...

The biotechnology space is extremely competitive, particularly cancer. Many of the people here that don't take my information at face value and instead attack my character are by default admitting they know nothing.

Go take a serious look at HER-VAXX. It failed badly, but everyone thought it was a success. It could have been significant at 95% CI, and it still probably would have failed because HER2 targeted therapies are so competitive.

The new age HER2 targeted agents are being tested against the prior HER2 targeted agents and not standard of care chemotherapy. If HER-VAXX went head to head with herceptin it would have lost, that's why it is in the bin.

People jump at a single mistake I made, but when you pool the data together for Azer-cel, it sits at 2nd last on that list of allogeneic compounds. This does not take into consideration the enormity of treatment options out there that are competing for market share in R/R DLBCL. Many of these options, once again, achieve better ORR and CR than Azer-cel currently.

You think I am negative, but I am being real.